Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

653
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
653
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Bone Disorders01:29

Bone Disorders

8.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
8.0K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

4.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
4.8K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

961
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
961
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass.

Bone research·2026
Same author

Deletion of the glucocorticoid receptor in osteoblasts and osteocytes drives trabecular bone loss in Col2.3-Cre and OG2-Cre knockout mice.

Bone·2026
Same author

[Preventive fields in endocrinology/diabetology-The big five].

Innere Medizin (Heidelberg, Germany)·2026
Same author

Pipe and cigar use, lung function decline and clinical outcomes: an analysis of the NHLBI Pooled Cohorts Study.

Thorax·2026
Same author

[Need for Improvement in Healthcare Provision for Rare Endocrinological Diseases in Germany Using the Example Endogenous Cushing's Syndrome].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))·2026
Same author

IgD-Expressing Mature B Cells Exhibit Enhanced Sensitivity to Glucocorticoid-Induced Cell Death.

European journal of immunology·2026

Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
05:55

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

1.1K

Glucocorticoid-Induced Osteoporosis.

Baruch Frenkel1, Wendy White, Jan Tuckermann

  • 1Department of Orthopaedic Surgery, Keck School of Medicine, Institute for Genetic Medicine, University of Southern California, 2250 Alcazar Street, CSC-240, Los Angeles, CA, 90033, USA, frenkel@usc.edu.

Advances in Experimental Medicine and Biology
|July 29, 2015
PubMed
Summary

Glucocorticoids (GCs) cause osteoporosis by harming bone-forming osteoblasts, inhibiting their growth, function, and survival. Targeting these mechanisms, like the Wnt pathway, is key for future treatments.

More Related Videos

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
06:16

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

8.1K
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.5K

Related Experiment Videos

Last Updated: Apr 6, 2026

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
05:55

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

1.1K
Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments
06:16

Preparation Of Gushukang GSK Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

8.1K
Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

1.5K

Area of Science:

  • Bone Biology
  • Endocrinology
  • Pharmacology

Background:

  • Glucocorticoid (GC) therapy is essential for inflammatory diseases but causes devastating osteoporosis.
  • GCs induce rapid skeletal effects, including decreased bone mineral density (BMD) and altered bone remodeling.
  • Osteoblasts are critically affected, leading to significant bone loss and increased fracture risk.

Purpose of the Study:

  • To review the deleterious effects of GCs on osteoblasts.
  • To elucidate the molecular mechanisms underlying GC-induced osteoporosis (GIO).
  • To discuss current and future therapeutic strategies for GIO.

Main Methods:

  • Review of existing human and mouse evidence on GC effects on bone.
  • Analysis of molecular pathways targeted by GCs in osteoblasts.
  • Discussion of therapeutic interventions for GIO.

Main Results:

  • GCs inhibit osteoblast replication, function, and survival through various pathways.
  • Key targeted pathways include growth factors, PI3-kinase, MAP kinase ERK, and critically, the Wnt signaling pathway.
  • GCs increase Wnt inhibitors and ROS, leading to ß-catenin loss and impaired osteoblast function.

Conclusions:

  • Osteoblast dysfunction is central to GC-induced osteoporosis.
  • GCs disrupt crucial regulatory mechanisms governing osteoblast biology.
  • Future therapies should target specific GC-affected pathways like Wnt, Notch, or RUNX2 for effective GIO management.